Photo of Dr Beatrice Seddon

Dr Beatrice Seddon

Telephone:

Email:

Location:

  • University College Hospital

GMC/GDC number:

3453405

Professional background

Dr Beatrice Seddon is consultant clinical oncologist on the Sarcoma Unit at University College Hospitals NHS Foundation Trust, specialising exclusively in the management (chemotherapy and radiotherapy) of soft tissue and bone sarcomas.

The sarcoma unit at UCLH, together with the sarcoma unit at the Royal National Orthopaedic Hospital, is the London Sarcoma Service (www.londonsarcoma.org) which offers a comprehensive clinical service to patients of all ages with sarcoma at all sites of the body. 

Dr Seddon trained in sarcoma oncology at the Middlesex Hospital and the Royal Marsden Hospital. She currently lectures and teaches on the management of sarcomas, and is actively involved in clinical research projects in this area. She is a member of the EORTC Soft Tissue and Bone Sarcoma Group and the NCRN Sarcoma Group.

Specialties

Research interests

Soft tissue and bone sarcomas

Gastrointesintal stromal tumours

Gynaecological sarcomas

Publications

  1. Best L, Seddon B, Woldman S, Lyon A, Illing R. Microwave ablation of pulmonary metastases associated with perioperative takotsubo cardiomyopathy. J Vasc Interv Radiol. 2014 Jul;25(7):1139-41. doi: 10.1016/j.jvir.2014.04.001.

  2. Amant F, Floquet A, Friedlander M, Kristensen G, Mahner S, Nam EJ, Powell MA, Ray-Coquard I, Siddiqui N, Sykes P, Westermann AM, Seddon B. Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S67-72. doi: 10.1097/IGC.0000000000000205.

  3. Reichardt P, Kang YK, Rutkowski P, Schuette J, Rosen LS, Seddon B, Yalcin S, Gelderblom H, Williams CC Jr, Fumagalli E, Biasco G, Hurwitz HI, Kaiser PE, Fly K, Matczak E, Chen L, Lechuga MJ, Demetri GD. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer. 2015 May 1;121(9):1405-13. doi: 10.1002/cncr.29220. Epub 2015 Jan 13.

  4. Seddon B, Scurr M, Jones RL, Wood Z, Propert-Lewis C, Fisher C, Flanagan A, Sunkersing J, A'Hern R, Whelan J, Judson I. A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma. Clin Sarcoma Res. 2015 May 16;5:13. doi: 10.1186/s13569-015-0029-8. eCollection 2015. 

  5. Seddon BM, Padley SP, Gazzard BG.    Parotid masses in HIV positive men: report of five cases and review. International Journal of STD & AIDS 1996; 7(3): 224-227.
  6. Sansom H, Seddon B, Padley SP. Clinical utility of abdominal CT scanning in patients with HIV disease.   Clinical Radiology 1997; 52(9): 698-703.
  7. Seddon B, Bidmead M, Wilson J, Khoo V, Dearnaley D. Target volume definition in conformal radiotherapy for prostate cancer: quality assurance in the MRC RT-01 trial. Radiotherapy and Oncology 2000; 56(1): 73-83.
  8. Seddon BM, Honess DJ, Vojnovic B, Tozer GM, Workman P. Measurement of tumour oxygenation: in vivo comparison of a luminescence fibre-optic sensor and a polarographic electrode in the P22 tumour. Radiation Research 2001; 55(6): 837-46.
  9. Seddon B, Cook A, Gothard L, Salmon E, Latus K, Underwood SR, Yarnold J. Detection of coronary artery disease in patients with early breast cancer treated with radiotherapy. Radiotherapy and Oncology 2002; 64(1): 53-63.
  10. Seddon BM, Maxwell RM, Honess DJ, Grimshaw R, Raynaud F, Tozer GM, Workman P. Validation of the fluorinated 2-nitroimidazole SR-4554 as a non-invasive hypoxia marker detected by magnetic resonance spectroscopy. Clinical Cancer Research 2002; 8(7): 2323-2335.
  11. Seddon B, Kelland L, Workman P. Bioreductive Prodrugs for Cancer Therapy. In: Springer CJ, Suicide Gene Therapy: Methods and Reviews. Totowa, USA: Humana Press Inc., 2003; pps 515-542.
  12. Seddon BM, Payne GS, Simmons L, Ruddle R, Grimshaw R, Tan S, Turner A, Raynaud F, Ford SJ, Leach MO, Judson I, Workman P. A phase I study of SR-4554 via intravenous administration for non-invasive investigation of tumour hypoxia by magnetic resonance spectroscopy in patients with malignancy. Clinical Cancer Research 2003; 9(14):5101-12.
  13. Seddon BM and Workman P. The role of functional and molecular imaging in cancer drug discovery and development. British Journal of Radiology 2004; 76 Spec No 2:S128-38.
  14. Seddon BM, Cassoni AM, Galloway MJ, Rees JH, Whelan JS. Fatal radiation myelopathy after high dose busulfan and melphalan chemotherapy and radiotherapy for Ewing’s sarcoma – a review of the literature and implications for practice. Clinical Oncology (R Coll Radiol) 2005; 17:385-390.
  15. Seddon BM. The role of imatinib mesylate in the management of advanced metastatic gastrointestinal stromal tumours and mechanisms of response and resistance. European Pharmacotherapy 2006 – November 2005. Touch Briefings. http://www.touchbriefings.com/pdf/1692/Seddon.pdf
  16. Whelan J, Seddon B, Perisoglou M. Management of Osteosarcoma. Current Treatment Options in Oncology 2006; &:444-455.
  17. Davda R, Seddon BM. Mechanisms and management of non-islet cell tumour hypoglycaemia in gastrointestinal stromal tumour: case report and a review of published studies. Clinical Oncology (R Coll Radiol); 2007;19:265-8.
  18. Roylance R, Seddon B, McTiernan A, Sykes K, Daniels S, Whelan J. Experience of the Use of Trabectedin (ET-743, Yondelistrade mark) in 21 Patients with Pre-treated Advanced Sarcoma from a Single Centre. Clin Oncol (R Coll Radiol) 2007; Jul 9.
  19. Seddon BM, Whelan J. Ewing’s sarcoma: Emerging Treatment Strategies and the Role of Treatment Stratification. Paediatric Drugs 2008; 10(2):93 – 105.
  20. Karavasilis V, Seddon B, Fisher C, Ashley S, Al-Muderis O, Judson I. Significant clinical benefit of palliative chemotherapy in advanced soft tissue sarcoma: Retrospective analysis and identification of prognostic factors in 488 patients. Cancer 2008; 112:1585-91.
  21. Windsor R, Strauss S, Seddon B, Whelan J. Experimental therapies in Ewing's sarcoma. Expert Opin Investig Drugs 2009 Feb;18(2):143-59.
  22. Montemurro M, Schöffski P, Reichardt P, Gelderblom H, Schütte J, Hartmann JT, von Moos R, Seddon B, Joensuu H, Wendtner CM, Weber E, Grünwald V, Roth A, Leyvraz S. Nilotinib in the treatment of gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer. 2009;45(13):2293-7.
  23. Lee CP, Payne GS, Oregioni A, Ruddle R, Tan S, Raynaud FI, Eaton D, Campbell MJ, Cross K, Halbert G, Tracy M, McNamara J, Seddon B, Leach MO, Workman P, Judson I. A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy. Br J Cancer. 2009;101(11):1860-8.
  24. Geh I, Miller B, Chambers RJ, Mahon B, Seddon B, Roy-Choudhury S. Upper GI tumours. In: Hoskin p, Goh V, Radiotherapy in Practice – Imaging. Oxford University Press, 2009; pps
  25. Grimer RJ , Judson IR, Peake D, Seddon B. Guidelines for the management of soft tissue sarcomas. Sarcoma 2010:506182: 1-15.
  26. Novelli M, Rossi S, Rodriguez-Justo M, Taniere P, Seddon B, Toffolatti L, Sartor C, Hogendoorn PC, Sciot R, Van Glabbeke M, Verweij J, Blay JY, Hohenberger P, Flanagan A, Dei Tos AP. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology 2010;57(2):259-70.
  27. Grimer R, Athanasou N, Gerrand C, Judson I, Lewis I, Morland B, Peake D, Seddon B, Whelan J. UK Guidelines for the management of bone sarcomas. Sarcoma. 2010;2010:317462. Epub 2010 Dec 29.
  28. Seddon BM and Davda, R. Gynaecological sarcomas: current status and future developments. Eur J Radiology (in press)
  29. Cassier P, Gelderblom P, Stacchiotti S, Thomas D, Maki R, Kroep J, van der Graaf W, Italiano A, Seddon B,  Dômont J, Bompas E, Wagner A, Blay J. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer 2011 Aug 5. doi: 10.1002/cncr.26409. [Epub ahead of print]
  30. Stubbs B, Desai A, Singh S, Seddon B, Khan F. Gastrointestinal stromal tumour in pregnancy. BMJ Case Reports 2011 (in press).
  31. Haas RL, Delaney TF, O'Sullivan B, Keus RB, Le Pechoux C, Olmi P, Poulsen JP, Seddon B, Wang D. Radiotherapy for Management of Extremity Soft Tissue Sarcomas: Why, When, and Where? Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):572-80. doi: 10.1016/j.ijrobp.2012.01.062. Epub 2012 Apr 18.
  32. Gelderblom H, Blay JY, Seddon BM, Leahy M, Ray-Coquard I, Sleijfer S, Kerst JM, Rutkowski P, Bauer S, Ouali M, Marreaud S, van der Straaten RJ, Guchelaar HJ, Weitman SD, Hogendoorn PC, Hohenberger P. Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An EORTC Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study. Eur J Cancer. 2014 Jan;50(2):388-96. doi: 10.1016/j.ejca.2013.10.002. Epub 2013 Nov 8.
  33. le Grange F, Cassoni AM, Seddon BM. Tumour volume changes following pre-operative radiotherapy in borderline resectable limb and trunk soft tissue sarcoma. Eur J Surg Oncol. 2014 Apr;40(4):394-401. doi: 10.1016/j.ejso.2014.01.011. Epub 2014 Feb 2
  34. Rothermundt C, Whelan JS, Dileo P, Strauss SJ, Coleman J, Briggs TW, Haile SR, Seddon BM What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients.. Br J Cancer. 2014 May 13;110(10):2420-6. doi: 10.1038/bjc.2014.200. Epub 2014 Apr 15